The Top 5 Biosimilars Articles for the Week of June 24

On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies

Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars

Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies

Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars

Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies

Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars

Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

Related Content

On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?

Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies

Podcast

On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.

Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars

In an article published in Frontiers in Pharmacy, researchers made recommendations to improve the biosimilar regulatory system and refine biosimilar guidelines in China.

Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

Podcast

On this episode of Not So Different, the FDA’s Sarah Yim, MD, discusses how the FDA is working to improve public trust in ophthalmology biosimilars and interchangeable products as part of a 3-part multimedia interview series.

White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings

The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively, and Altos Biologics completed patient enrollment for a phase 3 trial assessing an aflibercept biosimilar.